Click to Enlarge
The Financial Times’ main story focuses on a battle over the future of UK drug manufacturing giant GSK. US hedge fund Elliott Management, known for using its shareholdings to put pressure on companies’ management teams, has bought a multi-billion pound stake in GSK amid concerns by shareholders over the firm’s pipeline of future drugs and its R&D spending.